XLIX Annual Meeting of the European Histamine Research Society 2020

May 21-23, 2020, Düsseldorf/Mühlheim an der Ruhr – Wolfsburg, Germany

The 49th Annual Meeting of the European Histamine Research Society (EHRS) will not take place in Mülheim an der Ruhr, Germany, which is near Düsseldorf.

The 49th EHRS Meeting has been cancelled.

The fees paid so far will be paid back, but please give us some time to work-out the best procedure for this. We are also working on a new meeting in 2021 in Germany.

 

CONFERENCE MAIN TOPICS

  • Latest data of clinical trials on histamine receptor ligands in development including safety aspects
  • Clinical perspectives, patient studies
  • Novel therapeutic aspects
  • Preclinical developments
  • Pruritus, urticaria, asthma and food allergy
  • Pain, neuropathic pain
  • Sleep-wake state, narcolepsy
  • Histamine in the ear
  • Histamine in the eye
  • Histamine in the brain (neurodegenerative diseases, cognitive impairment etc.)
  • Histamine in the periphery
  • Histamine in gastrointestinal tract
  • Histamine and bacteria
  • Multitarget, multifunctional approaches for complex diseases
  • Around histamine, development of new biologically active compounds
  • CNS, neuroprotection, neuroinflammation
  • Cancer, inflammation, allergy, immune modulation (multiple sclerosis etc.)
  • Orphan disease (Prader-Willi Syndrome etc.)
  • Pitolisant, Toreforant, Seliforant etc.

 

INVITED SPEAKERS

Prof. Dr. Thomas Werfel – G. B. West Lecturer 2020, Deputy Director Medical University Hannover, Germany, Hannover Medical School, Professor for Immunodermatology and Experimental Allergy Research

Dr. Yves Auberson – Novartis Institutes for BioMedical Research, Executive Director, Global Discovery Chemistry, Basel, Switzerland, President of the European Federation of Medicinal Chemistry (EFMC)

Prof. Dr. Emanuela Masini, University of Firenze, Italy, Professor of Pharmacology and Toxicology, Neurofarba, Department of Neuroscience

Dr. Jonas Dyhrfjeld-Johnsen, Vice-President for Research and Translational Development at Sensorion-Pharma, Montpellier, France

Dr. Cate McCanless, Vice President for External affairs, Harmony Biosciences, Washington, USA (requested)

Verantwortlich für den Inhalt: E-Mail sendenUniv.-Prof. Dr. Dr. h.c. Holger Stark